Triple negative breast cancer (TNBC) is the breast cancer subtype characterized by the absence of expression of the ER, PR and HER2 (4).Therapies commonly used in other breast cancer subtypes are therefore not suitable for TNBC, and treatment options are largely limited to conventional genotoxic chemotherapy (5, 6). This evidence concerns the gene ESR1 and breast cancer.